فارسی
The CEBPA (CCAAT/enhancer-binding protein alpha) gene encodes a protein of the same name that is important for regulating the differentiation of blood cells. This protein is a transcription factor that binds to specific regions of DNA and helps control the activity of specific genes that play a role in the growth and development of certain blood cells. Additionally, this protein acts as a tumor suppressor, meaning that it is involved in cellular mechanisms that prevent irregular growth and division or an excess of cells.
Mutations in the CEBPA gene are associated with acute myeloid leukemia (AML) and acute myeloid leukemia. CEBPA mutations can be divided into two main categories. One category of mutations prevents the protein of this gene (as a transcription factor) from binding to DNA. Another category of mutations disrupts the translation process of the CEBPA protein and reduces its activity, which can play an important role in acute myeloid leukemia.
PCR-based mutation analysis is used to diagnose this disease. The CEBPA gene does not contain an intron, so to identify mutations in all AML patients, the entire coding region of the gene needs to be sequenced. Additionally, CEBPA gene mutations can also be inherited and cause acute myeloid leukemia in families.
Diagnostic tests for detecting changes in the CEBPA gene include:
- mutation analysis
- PCR sizing analysis
- and sequencing tests for mutation testing
